✦ LIBER ✦

GM-CSF an effective adjuvant for hepatitis B vaccine

Book ID: 120849312
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2007
Weight: 120 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200715700-00033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

GM-CSF improves immunogenicity of hepati

GM-CSF improves immunogenicity of hepatitis B vaccine in ESRD

📂 Article 📅 2006 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Use of GM-CSF as an adjuvant with cancer

Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

✍ Clive, Kevin S; Tyler, Josh A; Clifton, G Travis; Holmes, Jarrod P; Mittendorf, 📂 Article 📅 2010 🏛 Expert Reviews 🌐 English ⚖ 320 KB

Peripheral blood dendritic cells and GM-

Peripheral blood dendritic cells and GM-CSF as an adjuvantfor hepatitis B vaccination in hemodialysis patients

✍ VERKADE, MARTIJN A; VAN DE WETERING, JACQUELINE; KLEPPER, MARISKA; VAESSEN, LEON 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 110 KB

Efficacy of granulocyte-macrophage colon

Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection

✍ Maria das Graças Sasaki; Roberto Foccacia; Iara J.de Messias-Reason 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Efficacy of GM-CSF as an Adjuvant to Hep

Efficacy of GM-CSF as an Adjuvant to Hepatitis B Vaccination in Patients with Chronic Renal Failure—Results of a Prospective, Randomized Trial

✍ Singh, N. P.; Mandal, S. K.; Thakur, A.; Kapoor, D.; Anuradha, S.; Prakash, A.; 📂 Article 📅 2003 🏛 Informa plc 🌐 English ⚖ 226 KB

Immunization with an adjuvant hepatitis

Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease

✍ Ulrich Bienzle; Matthias Günther; Ruth Neuhaus; Pierre Vandepapeliere; Jens Voll 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 799 KB

Patients who undergo transplantation for hepatitis B virus (HBV)-related diseases are treated indefinitely with hepatitis B hyperimmunoglobulin (HBIG) to prevent endogenous HBV reinfection of the graft. Active immunization with standard hepatitis B vaccines in these patients has recently been report